Head-to-head evidence
Alirocumab vs AZD0780
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
Alirocumab · Praluent
Marketed by Regeneron Pharmaceuticals
NCT01507831 · Phase 3 · completed
The study was large (2,341 participants), randomized, quadruple-blind, and placebo-controlled. Its primary clinical safety endpoint was reported, but the registry does not provide a statistical significance test for the comparison, so whether the primary endpoint was met cannot be determined.
Next expected readout: December 2026 · NCT07477704 (registry estimate)
AZD0780
Developed by AstraZeneca
NCT06173570 · Phase 2 · completed
The study randomized 428 participants to four AZD0780 dose groups or matched placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the regulator-accepted lipid measure LDL cholesterol, and all four AZD0780-versus-placebo comparisons were statistically significant in the favorable direction (p<0.001).
Next expected readout: January 2027 · NCT07000136 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alirocumab's landscape · AZD0780's landscape